![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.83 | -2.09% | 38.94 | 33,776 | 11:43:04 |
|
£
|
Notes
|
Base salary
|
£850,000
|
The
comparator group for pay for the CFO role is the UK cross industry
comparator group.
|
Annual bonus
|
£850,000
|
The
on-target bonus would be 100% with a maximum of 200% as for the
existing CFO.
|
Award of LTIs
|
£1,700,000
|
This
assumes an expected value of 50% of an award of performance shares
under the Company's 2017 Performance Share Plan at a 4x multiple of
base salary as for the current CFO
|
Share Ownership Requirement (SOR)
|
300% of
base salary
|
This is
in line with GSK's shareholder approved executive remuneration
policy approved earlier in 2017.
|
Benefits and pension
|
|
Benefits
and pension will be in line with our policy and arrangements for
other senior executives based in the UK.
|
Sir
Philip
Hampton
|
Non-Executive
Chairman
|
Ms Emma
Walmsley
|
Chief
Executive Officer
|
Mr
Simon Dingemans
Mr Iain
Mackay
|
Chief
Financial Officer
Chief
Financial Officer Designate
|
Dr Hal
Barron
|
Chief
Scientific Officer & President, R&D
|
Mr
Vindi Banga
|
Senior
Independent Non-Executive Director
|
Dr
Vivienne Cox
|
Independent
Non-Executive Director
|
Ms Lynn
Elsenhans
|
Independent
Non-Executive Director
|
Dr
Laurie Glimcher
|
Independent
Non-Executive Director
|
Dr
Jesse Goodman
|
Independent
Non-Executive Director
|
Ms Judy
Lewent
|
Independent
Non-Executive Director
|
Mr Urs
Rohner
|
Independent
Non-Executive Director
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors' in the company's Annual Report on Form 20-F for
2017.
|
Registered in England & Wales:
No.
3888792
|
|
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: 07
August, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions